Pregled bibliografske jedinice broj: 881000
Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars
Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars // Expert opinion on biological therapy, 17 (2017), 8; 915-926 doi:10.1080/14712598.2017.1341486 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 881000 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Is there a reason for concern or is it just hype? – A
systematic literature review of the clinical
consequences of switching from originator biologics
to biosimilars
Autori
Inotai, András ; Prins, Christiaan ; Csanádi, Marcell ; Vitezić, Dinko ; Codreanu, Catalin ; Kaló, Zoltán
Izvornik
Expert opinion on biological therapy (1471-2598) 17
(2017), 8;
915-926
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
biosimilar ; immunogenicity ; patient access ; risk ; societal benefit ; substitution ; switch
Sažetak
Introduction: While prescribing biosimilars to patients naive to a biologic treatment is a well- accepted practice, switching clinically stable patients from an originator to a biosimilar is an issue for clinicians. Well designed clinical trials and real-world data which study the consequences of switching from an originator biologic treatment to its biosimilar alternative are limited, especially for monoclonal antibodies. Areas covered: A systematic literature review was conducted on PubMed to identify evidence of the consequences of switching from original biologics to biosimilars. References of included papers were also scrutinized. After a title-, abstract- and full text screening, out of the 153 original hits and 77 additional ones from screening the references, 58 papers (12 empirical papers, 5 systematic reviews and 41 non-empirical papers) were included. Expert opinion: Preventing patients on biologic medicines from switching to biosimilars due to anticipated risks seems to be disproportional compared to the expected cost savings and/or improved patient access. Indeed, it is the opinion of the authors that the concern of switching to biosimilars is overhyped.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
MZOS-062-0620063-0060 - Uporaba kardiovaskularnih lijekova i značaj farmakoekonomskih procjena (Vitezić, Dinko, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Rijeka,
Klinički bolnički centar Rijeka
Profili:
Dinko Vitezić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE